Podcasts about In vivo

Face au dérèglement climatique et aux crises diplomatiques, penser le temps long pour les agriculteurs est essentiel. C'est ce que peut faciliter le modèle coopératif. Thierry Blandinières, président de l'union nationale des coopératives agricoles et un des premiers groupes européens agricoles, Invivo, explique que l'agriculture régénératrice peut être un moyen de concilier transition écologique et souveraineté. ----------------------------------------------------------------------- SMART IMPACT - Le magazine de l'économie durable et responsable SMART IMPACT, votre émission dédiée à la RSE et à la transition écologique des entreprises. Découvrez des actions inspirantes, des solutions innovantes et rencontrez les leaders du changement.

Aujourd'hui, j'avais envie de vous partager un épisode qui m'a vraiment marqué. Il s'agit d'une interview de Sébastien Graff, directeur général en charge des ressources humaines et des projets stratégiques chez InVivo, dans le podcast Topo RH. Ce que j'ai particulièrement apprécié, c'est la façon très concrète dont il parle de la croissance par acquisition, mais surtout de l'humain derrière ces transformations. Comment intégrer des équipes, créer une culture commune, éviter les chocs… C'est à la fois très lucide, très structuré, et profondément inspirant. Un épisode que je vous recommande vraiment d'écouter si vous vous intéressez au management et aux enjeux RH d'aujourd'hui. Bonne écoute

Clint, Meg and Dan kick off a short week with Producer Nepia's homemade cinnamon scrolls, a reminder that EZ Money’s $10,000 must be won by Wednesday, and a last chance to win a Harry Styles flyaway. They debate throwback tracks, chat celebrity wine collaborations with InVivo’s Tim (including Graham Norton and Sarah Jessica Parker), and play “more or less” time-zone trivia. The show covers Swedish “grab dad ass” research, a KitKat truck heist, big Lotto wins, Meghan Markle’s dad’s new relationship, and listeners’ biggest achievements by 19. EZ Money callers fall short, Dan discovers his wife’s box of ex memorabilia, fuel price winners are announced, and a Holden driver wins $200 in Fuel It. 00:00 Breakfast Show Kickoff02:14 Throwback Song Debate06:54 Weekend Paint Fail10:36 First Call of the Day14:54 More Or Less Timezones27:25 EZ Money Challenge30:26 Beauty Pageant Blunders34:47 Age Gaps39:36 Raye Album Spotlight44:04 What did you do at 19?52:47 EZ Money Challenge54:25 Exes Keepsakes Box01:02:10 Cheapest Fuel Countdown01:04:44 One of the Girls Quiz01:08:17 Fuel Wheel Winner

Bronchopulmonary dysplasia affects up to 90% of extremely preterm infants, yet no approved therapies exist. In this episode of the In Vivo podcast, Airway Therapeutics CEO Marc Salzberg discusses how their Phase Ib study of zelpultide alfa, a recombinant surfactant protein D, showed substantial reductions in BPD incidence and mechanical ventilation time. Salzberg explains the unique challenges of running neonatal trials, navigating regulatory pathways for vulnerable populations, and why preventing BPD could unlock broader respiratory applications. From ethics and enrollment to EMA approval and global expansion, this episode explores what it takes to develop breakthrough medicines for the smallest, most fragile patients.

Tim Lu, CEO of Senti Bio, joins In Vivo to discuss how programmable cell therapies are solving oncology's targeting problem. Lu explains the logic-gated approach behind SENTI-202, an allogeneic CAR-NK therapy for relapsed/refractory AML that achieved 50% response rates in Phase 1 while avoiding the dose-limiting toxicities that have plagued other AML cell therapies. We cover the Phase 1 ASH 2025 data showing 39% complete remission rates (all MRD-negative) with 7.6-month median duration, the rationale for using NK cells over T cells, and why synthetic biology's three-target logic gates can distinguish cancer from healthy bone marrow cells. Lu also discusses plans for pivotal trials following RMAT designation, expansion into solid tumors, and where biotech innovation is accelerating versus where clinical translation bottlenecks remain. For biopharma professionals tracking cell therapy innovation, synthetic biology applications, and AML treatment advances.

Scrip senior editor Jessica Merrill, Scrip US managing editor Mandy Jackson and In Vivo senior reporter David Wild discuss trends and topics from interviews and presentations at the J.P. Morgan Healthcare Conference and Biotech Showcase.

Dans son émission, Judith Beller reçoit le chanteur Dave et le patron du groupe InVivo, Thierry Blandinières

Intranasal vaccines are back in the spotlight as highly pathogenic avian influenza spreads among birds and spills over into mammals, including recent cases in dairy and poultry workers. In this episode of In Vivo, senior pharma and biotech reporter David Wild talks with Chad Costley, CEO of BlueWillow Biologics and Meagan Deming, an infectious disease researcher at the University of Maryland School of Medicine about a novel intranasal recombinant H5 flu vaccine that aims to stop infection at the gate by building mucosal immunity in the nose. They discuss recent Phase I data, pandemic‑flu preparedness, BARDA/NIH funding realities, and how BlueWillow's NanoVax platform could extend to other major respiratory threats, including TB.

Drug resistance derails even the most advanced cancer treatments, but what if we could restore sensitivity to existing therapies instead of starting over? Neil Bhowmick, chief scientific officer at Kairos Pharma, joins In Vivo to discuss how his company is tackling resistance in oncology. We explore the company's lead asset, ENV-105, which is showing over 13 months of progression-free survival in Phase II prostate cancer trials by resensitizing tumors to hormone therapy, with significantly lower toxicity than standard alternatives like chemotherapy or radiopharmaceuticals. Bhowmick explains the complex biology behind different resistance mechanisms, shares early data on GITR-modulating therapies designed to expand T cell populations for immunotherapy, and discusses their approach to developing companion biomarkers for patient selection. We also dive into the clinical and commercial rationale for combination approaches and what milestones to watch in the coming year.

L'Union européenne est l'un des plus grands producteurs mondiaux de céréales. Mais depuis trois ans, le secteur est pris en étau entre des prix planchers sur des marchés internationaux volatils et la hausse des coûts de production. Sans parler de l'impact des aléas climatiques sur les rendements. Comment vont les céréaliers aujourd'hui ? Quelles sont les perspectives pour les céréales européennes ? Le 62ème épisode de Nourrir l'Europe tente de répondre à ces questions. Eric Thiroin, céréalier français et président de l'Association générale des producteurs de blé, nous rapporte la dégradation de la compétitivité et du moral de la profession dans l'Union européenne depuis le début de la guerre en Ukraine. Guillaume Jacquemin, sélectionneur céréales au Centre de recherche agronomique de Wallonie, nous explique comment se créent, dans l'UE, les nouvelles variétés de céréales résistantes aux évolutions du climat. Et Philippe Mitko, responsable des relations extérieures de Soufflet Négoce by InVivo, décrypte ce qui détermine les prix des céréales sur les marchés internationaux et l'exposition des producteurs européens aux effets de change. Enfin, Justyna Wrobel, qui dirige l'équipe en charge des céréales, des oléagineux, des légumineuses et du riz dans l'unité cultures arables de la Direction générale de l'agriculture et du développement rural de la Commission européenne, revient sur la nature du soutien apporté par la Politique agricole commune aux céréaliers européens dans cette période difficile et sur les pistes envisagées pour renforcer la compétitivité du secteur.

The European Union is one of the world's largest producers of cereals. But for the past three years, the sector has been caught between low prices on volatile international markets and rising production costs, not to mention the impact of climate change on yields. How are cereal farmers doing today? What is the outlook for European cereals? The 62nd episode of Food for Europe attempts to answer these questions. Eric Thirouin, a French cereal farmer and president of the General Association of Wheat Producers, reports on the deterioration in the competitiveness and morale of the profession in the European Union since the start of the war in Ukraine. Guillaume Jacquemin, cereal breeder at the Agricultural Research Centre of Wallonia, explains how new varieties of cereals that are resistant to climate change are being created. And Philippe Mitko, head of external relations at Soufflet Négoce by InVivo, tells us about the factors that determine the prices of cereals on international markets and the exposure of European producers to exchange-rate fluctuations. Finally, Justyna Wrobel, who heads the cereals, oilseeds, pulses and rice team in the Arable Crops Unit of the European Commission's Directorate-General for Agriculture and Rural Development, discusses the nature of the support provided by the Common Agricultural Policy to European cereal producers in this difficult period, and the ways in which the sector's competitiveness can be strengthened.

Die Europäische Union ist einer der weltweit größten Getreideproduzenten. Seit drei Jahren jedoch befindet sich der Sektor in einer Zwickmühle zwischen Tiefstpreisen auf volatilen internationalen Märkten und steigenden Produktionskosten. Ganz zu schweigen von den Auswirkungen der Klimakatastrophe auf die Erträge. Wie geht es den Getreidebauern heute? Wie sehen die Aussichten für europäisches Getreide aus? Antworten auf diese Fragen gibt es in dieser 62. Folge von 'Nahrung für Europa'. Eric Thiroin, französischer Getreidebauer und Vorsitzender der Association générale des producteurs de blé (Allgemeiner Verband der Weizenproduzenten), berichtet über die Verschlechterung der Wettbewerbsfähigkeit und der Stimmung in der Branche in der Europäischen Union seit Beginn des Krieges in der Ukraine. Guillaume Jacquemin, Getreidezüchter am Wallonischen Agarforschungszentrum, erklärt, wie in der EU neue Getreidesorten gezüchtet werden, die gegen Klimaveränderungen resistent sind. Und Philippe Mitko, Leiter der Abteilung für Außenbeziehungen bei der französischen Getreidehandelsgrupp Soufflet Négoce by InVivo, analysiert, was genau die Getreidepreise auf den internationalen Märkten bestimmt und inwiefern die europäischen Erzeuger den Wechselkursschwankungen ausgesetzt sind. Schließlich berichtet Justyna Wrobel, Leiterin des Teams für Getreide, Ölsaaten, Hülsenfrüchte und Reis in der Abteilung Ackerkulturen der Generaldirektion Landwirtschaft und ländliche Entwicklung der Europäischen Kommission, über die Art der Unterstützung, die die Gemeinsame Agrarpolitik den europäischen Getreidebauern in dieser schwierigen Zeit gewährt, und über die geplanten Maßnahmen zur Stärkung der Wettbewerbsfähigkeit des Sektors.

In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.

Synopsis: Nimbus Therapeutics CEO Abbas Kazimi walks Alok Tayi through the company's evolving pipeline and playbook for choosing the right risks in a noisy biotech environment. From Werner helicase for MSI-high cancers to a highly selective SIK2 program and GLP-1–adjacent strategies focused on body composition, Abbas details how Nimbus balances rigor, speed, and capital efficiency. He shares candid lessons from pausing and later resurrecting AMPK beta in partnership with Eli Lilly, the decision to remain modality-agnostic but small-molecule-centric, and the importance of knowing when not to chase the latest fad. Throughout, Abbas returns to a consistent theme: success at Nimbus comes from disciplined target selection, deep collaboration, and a culture that empowers teams to make hard calls in service of patients rather than headlines. Biography: Abbas Kazimi is the Chief Executive Officer of Nimbus Therapeutics. Previously, he served as Chief Business Officer, leading the company's strategic and corporate development efforts while overseeing business operations. Since joining Nimbus in 2014, he has helped raise over $630 million in equity financing and led transactions totaling more than $8 billion. Notably, Mr. Kazimi spearheaded the $6 billion sale of Nimbus's TYK2 program to Takeda, the $1.2 billion sale of its NASH (ACC) program to Gilead, and multiple licensing deals exceeding $1.5 billion with partners such as Genentech, Celgene/Roche, and Eli Lilly. Under his leadership, Nimbus has advanced four programs into the clinic, returned over $4 billion to investors, and continues to expand its computational drug discovery and clinical development capabilities. In 2025, Mr. Kazimi joined the board of Unnatural Products (UNP), a biotech company pioneering orally delivered macrocyclic peptides to tackle previously undruggable targets. He also serves on the Editorial Advisory Board for In Vivo magazine, a leading publication offering strategic insights and analysis of the pharmaceutical, biotechnology, medtech, and consumer health industries. Along with his family, he established the Kazimi Family Endowment for Data Science in Oncology at MD Anderson Cancer Center. This endowment reflects their personal commitment to philanthropy and their vision for revolutionizing cancer treatment through data-driven innovation. At the core of Mr. Kazimi's leadership is a deep sense of purpose—one that seeks to change the trajectory of medical diagnoses where options are limited. The ability to give patients, prescribers, and families a new outlook on life is a powerful responsibility—and one he knows the biopharmaceutical sector has the ability to fulfill. Before Nimbus, he was at Extera Partners, LLC (formerly PureTech Development, LLC), where he provided strategic advisory, supported fundraising, and executed numerous business development transactions. Earlier in his career, he was with JSB-Partners, LP, a specialized investment banking and advisory firm serving biotech and pharmaceutical companies. Mr. Kazimi holds a B.A. from the University of Texas at Austin and an M.S. from Harvard University.

In Vivo spoke with Emma Johnson, CEO of Essential Pharma, to discuss the company's strategic priorities and plans for growth as it expands its portfolio in rare diseases.

The UK can't seem to get enough of New Zealand wine. Latest data shows Sauvignon Blanc shipments hit a 10 year high – with 13.2 million bottles sent over summer. Exports are up 21% year on year, New Zealand now commanding around half of the $2.5 billion UK Sauvignon Blanc market, valued at NZ$1.37 billion. Invivo Co-founder Tim Lightbourne told Mike Hosking there's been a shift in the UK away from heavy reds, with Sauv becoming the go to over things like Malbec, Shiraz, and Merlot. Plus, New Zealand wines are a premium to the category, he says, selling for about 17% more than the average bottle. LISTEN ABOVE See omnystudio.com/listener for privacy information.

In Vivo spoke with Annette Bakker, CEO of the Children's Tumor Foundation, a medical research foundation developing an innovative approach to reviving shelved pharmaceutical assets, resulting in the recent US FDA approval of mirdametinib, a treatment for rare tumors.

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. Its CEO and CFO discuss with In Vivo the company's rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

The latest episode of the In Vivo podcast features an interview Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP at Astellas Gene Therapies, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds.

The latest episode of the In Vivo podcast features an interview with Phil L'Huillier, who discusses the inclusion of Scancell's melanoma cancer vaccine on the NHS Cancer Vaccine Launch Pad, and how 2025 could be a pivotal year for the cancer vaccine field as a whole.

The latest episode of the In Vivo podcast features an conversation with Agnès Arbat, CEO and co-founder of Barcelona-based biotech company OxoLife, which is pioneering a novel approach to addressing female infertility.

Send us a textEver wonder about those little details that could make or break your licensure exam score? This episode dives deep into the crucial distinction between in vivo and in vitro therapeutic interventions—concepts that might seem mundane but could tip the scales in your favor come exam day.We break down in vivo interventions, which take place in clients' natural environments where their challenges typically emerge. From the Latin meaning "alive" or "life," these approaches involve guiding clients through therapeutic processes in authentic contexts. Picture a therapist accompanying a client with agoraphobia to a Taylor Swift concert to practice coping skills amid genuine triggers, or meeting a family in their home to address actual family dynamics. The beauty of in vivo therapy lies in its immediate relevance to clients' daily experiences, allowing for direct practice with real-world challenges.Contrasting this, we explore in vitro interventions—stemming from the Latin word for "glass-like," evoking the image of a test tube artificially containing substances. These approaches occur in controlled clinical settings using simulations, role-playing, or structured exercises. From virtual reality sessions simulating airplane travel for clients with flying phobias to role-playing job interviews in the safety of your office, in vitro methods offer a protected space for skill development before real-world application. We also cover similar techniques like imaginal exposure, systematic desensitization, and simulated exposure therapy that fall under this umbrella.Whether you're preparing for your licensure exam or simply expanding your therapeutic toolkit, understanding these approaches enhances your ability to provide effective, context-appropriate interventions. And if you get the chance, take our advice and check out VR experiences of the International Space Station or Machu Picchu—both are pretty amazing ways to experience the power of simulated environments!If you need to study for your national licensing exam, try the free samplers at: LicensureExamsThis podcast is not associated with the NBCC, AMFTRB, ASW, ANCC, NASP, NAADAC, CCMC, NCPG, CRCC, or any state or governmental agency responsible for licensure.

관세와 무역 장벽의 출현, 정책 변화 등으로 올해 유럽 바이오기업들의 자금조달이 쉽지 않은 상황이라는 In Vivo 기사를 요약한 내용입니다. https://insights.citeline.com/in-vivo/market-intelligence/the-360-degrees-of-european-biotech-financing-in-2025-KZUNCOS3GZAYLBPGFTLJUBY7SY/ Join Seoul-based Scrip and Pink Sheet editor Jung Won Shin in this Korean-language mini podcast on recent biopharma industry topics. Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

Dans “La France bouge”, Elisabeth Assayag fait le tour de France des initiatives positives et novatrices. Travail, éducation, santé… Ils œuvrent aux quatre coins du pays pour faire bouger les lignes et casser les codes : qui sont ces citoyens, ces entreprises, ces collectivités qui s'engagent et inventent le monde de demain ? Des portraits et des témoignages inspirants.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding and validating RNA therapies for chronic liver diseases.

New Zealand's wine industry could suffer as a result of Donald Trump's new tariffs, with the United States our largest export market. Invivo co-founder Rob Cameron spoke to Ingrid Hipkiss.

We love to hear from our listeners. Send us a message. After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year journey covering the pharmaceutical space, from Haymarket Media to PwC to Pharmaceutical Executive and InVivo magazines, before joining Life Science Connect as Chief Editor at Life Science Leader. He shares stories of the wild ride he's enjoyed along the way, how the stories he's covered have shaped his editorial perspective, and his plans for the next chapter of the Business of Biotech podcast. Catch Ben's first episode as host next Monday, and every Monday after that. Subscribe to the podcast on your preferred platform and watch the videocast at lifescienceleader.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In Vivo spoke with UK biotech CEO Catherine Pickering about developing innovative therapies for challenging cancer types, the progress of iOntura's lead asset, roginolisib, for uveal melanoma, and the strategies that have helped secure over €100m in private financing.

New Zealand winemakers are continuing to make moves in the US. Amid an uncertain market, we were the only nation in the top ten US wine suppliers to increase its volume last year. Data suggests it's the 16th year in a row New Zealand wine has reported growth. Invivo Wine Founder Tim Lightbourne told Mike Hosking there's big opportunities over in the States, with New Zealand wines being sold right around the country. LISTEN ABOVE See omnystudio.com/listener for privacy information.

In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based agentic AI that streamlines clinical trial processes.

Harness Therapeutics' CEO talked to In Vivo about the company's scientific strategy, and its plans for expansion and partnering in the neurodegeneration space.

In Vivo speaks with Ashley Zender, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals. The company's $494m partnership with Eli Lilly is a testament to the value of their approach.

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

How do you start a wine making partnership with Sarah Jessica Parker? It turns out, all you have to do is ask - as long as you have an award-winning wine brand and savvy business partners with years of experience. In this special episode, we have the pleasure of speaking with New Zealanders and business partners Tim Lightbourne and Rob Cameron of Invivo - where Rob is the winemaker and Tim is the director. After getting their degrees in physiology and one of them starting a pain relief cream business (not a joke), these childhood friends found themselves at a pub in England and hatched the plan for Invivo wines. Years of sweat and grit got them to where they are today, with an internationally known and distributed wine brand, and collaborations with Graham Norton and Sarah Jessica Parker. And in case you think these are just names slapped on the labels, Tim and Rob ensure that Norton and SJP are directly involved in the blending of their wines. Listen in to hear about their fascinating story, how storytelling is at the center of what they are trying to create, and learn more about their motto “Break Dumb Rules.”Send us a Text Message and we'll respond in our next episode!Contact The Wine Pair Podcast - we'd love to hear from you!Visit our website, leave a review, and reach out to us: https://thewinepairpodcast.com/Follow and DM us on Instagram: https://www.instagram.com/thewinepairpodcast/Send us an email: joe@thewinepairpodcast.com

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company's monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations.

Does wine feel too complicated? In this episode of Wine Talks, Paul K sits down with Tim Lightbourne and Rob Cameron, the founders of Invivo Wines, to explore how they've transformed the wine industry. Ditching the stuffy, aristocratic vibe traditionally associated with wine, Invivo has redefined the game with bold creativity and a focus on fun and inclusivity. They reveal the power of their celebrity collaborations with Sarah Jessica Parker and Graham Norton–partnerships that go beyond simple endorsements. Discover how Invivo is pushing the boundaries of wine marketing, including launching their winery airline and hosting quirky blending sessions designed to craft the perfect wine bottle. This episode is truly a masterclass in balancing authenticity with wine branding, navigating industry challenges, and rewriting the rules in a competitive market. Don't miss this eye-opening conversation!   Key Takeaways: Introduction (00:00) Invivo's “100% bullshit-free” wine philosophy (00:38)  Making wine accessible for younger consumers (02:16) How Rob and Tim pioneered equity crowdfunding in wine (06:00) Invivo's founding story and innovative marketing (09:08) Understanding consumer tastes and regional differences (12:06) Invivo's innovative celebrity collaborations (22:09) Wine industry's need for creativity and marketing innovation (44:17) Episode wrap-up (48:13)   Additional Resources:

In the latest episode of the In Vivo podcast, Noam Solomon, co-founder and CEO of Israeli-American biotech Immunai explains how his company is mapping the immune system and using AI to predict individual immune responses to drugs. Noam also discusses the company's own acquisitions, partnerships, the differences between innovation and invention, artificial biomedical intelligence (ABI) and barriers to personalized medicine.

Americans seem to love New Zealand wine. Grafton-based Invivo was flying off US shelves, selling more than 40,000 cases of sauvignon blanc in 2024 alone. It's set to be on show in Times Square at an exclusive wine exhibition this week, run by Wine Spectator. Co-founder Tim Lightbourne told Mike Hosking that both New Zealand wine and sauvignon blanc are growing as categories in the US market. He said that wine as a whole is relatively flat and driven by cabernets and chardonnays, so there's room to NZ sauvs to grow. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.

In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind Amprion, a diagnostics company, discusses the role of alpha-synuclein misfolding in neurodegenerative diseases and how early alpha-synuclein detection has the potential to mitigate the impacts of diseases ranging from Parkinson's disease to Lewy body dementia.

In the latest episode of the In Vivo podcast, Alan Aspuru-Guzik, a pioneer in chemical engineering who holds many positions, talks about how he is folding in robotic automation, generative AI and quantum computing in his self-driving lab.

In this episode of the In Vivo podcast, Billy Boyle, CEO of Owlstone Medical, discusses how his company is developing several breath biopsy products for use by clinicians, biopharma companies and researchers.

Mr. Happy | The Next Generation - Part 2Tune into the second half of our fascinating conversation with Joshua, A.K.A. Mr. Happy from the famous Mr. Happy Stack. We discuss more insight on how the microbiome, immune system, hormones and neurotransmitters are connected. These systems rely on us to exercise, to eat well, and to be able to recover. However, our lifestyle, food supply, and other factors can make it difficult to maintain a healthy baseline. And further, how do supplements play a part in all of this?Part 2 of the podcast is an activating deep-dive that motivates us to take our health seriously, and better understand the main factors that allow us to live long, healthy and happy lives. These are the immune system, the microbiome, the hormone biosynthesis system, and our diets.Click to Learn More About Joshua's Immune System Researchhttps://bornfree.life/understanding-the-model/6/updated-disease-model-wip/45/1:20 In Vivo vs. In Vitro5:20 The Importance of the Micro-Biome14:55 Mineral Deficiencies18:00 Dietary Minerals23:30 Bio-films and the Immune System28:00 Dopamine Synthesis and Nootropics35:00 Hormone Biosynthesis42:00 Testing Our Microbiome + Bacterias44:40 Getting to the Root of Hormonal Imbalance47:00 Are Male Testosterone Levels Dropping?50:00 NADH Supplementation56:00 The Importance of Exercise57:00 The Importance of Libido1:03:00 Which Tests Work Best for Microbiome1:05:30 Understanding Our Microbiome1:11:00 Conclusion

With its potential to expand the horizons of what's possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

This episode is from a webinar presented by Dr. Clay Zimmerman, Director of Technical Services at Balchem. To view the full webinar and access the slides referenced during this podcast, visit balchem.com/realscience and scroll down to the webinar presented on December 12th, 2023.Dr. Zimmerman begins with an overview of Balchem's microencapsulation technologies in both human nutrition and health and animal nutrition and health businesses. (0:31)Encapsulation is a generic term, and huge differences can exist between products that protect the same compound. Balchem's microencapsulation technology consists of packaging a substance in a lipid capsule for protection. Encapsulates can differ in design, technology, and performance. When it comes to performance in ruminant encapsulates, stability in feed mixing and TMRs and animal performance are evaluated. (6:50)Lipid encapsulation usually comes in one of two forms, a matrix encapsulation or a true encapsulation. A good analogy for matrix encapsulation is chocolate chip cookie dough, where some active compound is always at the surface. In the rumen, this leads to reduced protection and stability. True encapsulation, often called single-layer or multiple-layer encapsulation, is analogous to an m&m where there is no active compound at the surface, and this leads to greater protection and stability in the rumen.  (12:00)So why do we encapsulate nutrients for ruminants? In general, for targeted delivery within the gastrointestinal tract of the animal because rumen fermentation often results in massive breakdown of most of these important compounds. For example, choline chloride is almost completely degraded in the rumen. (18:30)When developing or improving rumen-protected products for nutrients such as choline chloride, methionine, lysine, or niacin, the primary goal is to protect them as much as possible from ruminal degradation while achieving post-ruminal absorption. Once prototypes have good ruminal stability and good intestinal release, the next step is feed and mixing stability. Dr. Zimmerman goes on to showcase different research techniques for evaluating encapsulates in these three areas as well as in animal performance. (20:39)In summary, there are many differences in encapsulated products for dairy cows, due to the design of products; types, amount, and composition of coatings; manufacturing differences; and differences in nutrient content, bioavailability, and feed stability. True encapsulates, or multi-layered coating products, are preferred for ruminant applications due to their higher levels of ruminant and feed stability. Four really important features of a good ruminant encapsulate are good ruminal stability, good nutrient bioavailability, feed and TMR stability, and ultimately biological performance. (47:05)Dr. Zimmerman then answers questions from the webinar audiences about in vitro techniques and bioavailability, coating ingredients, the importance of base diet for rumen fluid donors in in vitro techniques, variation in products from in vitro to in vivo results, how long it takes to develop a new encapsulated product (Balchem spends years and even decades researching before a product release), and why nutrient contents differ so much in similar encapsulated products on the market. (49:58) Please subscribe and share with your industry friends to bring more people to join us around the Real Science Exchange virtual pub table.  If you want one of our new Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll get a shirt in the mail to you.